PERSPECTIVE article
Front. Physiol.
Sec. Metabolic Physiology
This article is part of the Research TopicImmunoregulation and Inflammation Interventions in Nutritional Metabolic DiseasesView all 6 articles
Hypoxia-Inducible Factors in the Immunometabolism of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Molecular Mechanisms and Therapeutic Implications
Provisionally accepted
- 1Infectious Diseases Major, Qinghai University, Xining, China
- 2Department of Hepatology II, Fourth People’s Hospital of Qinghai Province, Xining, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Metabolic dysfunction-associated steatotic liver disease (MASLD) has become a predominant cause of liver disease globally, primarily due to the rising prevalence of metabolic disorders, including obesity and diabetes. The advancement of MASLD from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis involves intricate metabolic and immune interactions. Hypoxia-Inducible Factors (HIFs) are integral to the regulation of cellular responses under hypoxic conditions, significantly influencing metabolic homeostasis and modulating immune cell functions. Within the framework of MASLD, HIFs facilitate the adaptive responses to hypoxic conditions and oxidative stress, which are pivotal drivers of disease progression. However, the precise mechanisms by which HIFs influence MASLD pathogenesis remain incompletely understood. This study seeks to investigate the role of HIFs in the immunometabolic processes of MASLD, with particular emphasis on the molecular pathways they regulate within hepatic cells and the immune microenvironment. Furthermore, we examine the challenges associated with therapeutically targeting HIFs, such as the intricate regulation of HIFs, their tissue-specific effects, and the potential risk of inducing tumorigenesis. In conclusion, we underscore prospective research avenues that may yield innovative therapeutic strategies aimed at targeting HIFs to alleviate inflammation, fibrosis, and metabolic dysregulation in MASLD.
Keywords: Fibrosis, hypoxia, Hypoxia-inducible factors, Immunometabolism, Lipid Metabolism, liver inflammation, MASLD, Therapeutic targeting
Received: 04 Feb 2026; Accepted: 10 Feb 2026.
Copyright: © 2026 Zhao, Wang, Li and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Guoying Yu
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.